In preclinical studies, pharmacological inhibition or genetic manipulation of autophagic regulators such as autophagy-related proteins (ATGs), mammalian target of rapamycin (mTOR), and phosphatidylinositol 3-kinase catalytic subunit type 3 (PI3KC3) have been shown to sensitize tumor cells to chemotherapy-induced cell death [9, 12, 13]. This evidence concerns the gene MTOR and neoplasm.